PainReform Ltd.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PainReform Ltd. is a pharmaceutical company, which focuses on reformulation of established therapeutics. It offers PRF-110, an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed prior to closure to provide localized and extended post-operative analgesia. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.

PainReform (NASDAQ: PRFX ) stock is falling on Wednesday after the company announced a concurrent registered direct offering and private placement. The registered direct offering has PainReform agreeing to sell 301,230 shares of PRFX stock at a price of $9 per share.

Why Is PainReform (PRFX) Stock Down 40% Today?

TEL AVIV, Israel, July 12, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that it has entered into a definitive agreement for the purchase and sale of 301,230 of the Company's ordinary shares (or pre-funded warrants in lieu thereof), at a purchase price of $9.00 per ordinary share, in a registered direct offering. In a concurrent private placement, the Company has agreed to issue in the offering unregistered warrants to purchase up to an aggregate of 301,230 ordinary shares. The offering is expected to close on or about July 14, 2023, subject to satisfaction of customary closing conditions.

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

TEL AVIV, Israel, June 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will be presenting at the Maxim Group Virtual Healthcare Conference, hosted by M-Vest, which is being held June 20-22, 2023.

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

TEL AVIV, Israel, June 07, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a regulatory update on the second part of its Phase 3 clinical trial of PRF-110 in patients undergoing bunionectomy surgery. The Company's supplier of the API (active pharmaceutical ingredient) has received a deficiency notice from the FDA related to its Drug Master File (DMF). The DMF is the file on record with the FDA representing the manufacturing process and facility for the production of the API. As a result, the second part of the Phase 3 trial is expected to commence once the required information has been provided by the supplier to the FDA and the deficiency notice has been resolved. None of the issues raised relate to the Company's PRF-110 product.

PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

Reports Progress on Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery Reports Progress on Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

PainReform Provides Business Update for the First Quarter of 2023

Reports Solid Safety Profile of PRF-110 and No Serious Adverse Events among First 15 Patients Reports Solid Safety Profile of PRF-110 and No Serious Adverse Events among First 15 Patients

PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

First 15 patients administered PRF-110 intra-operatively First 15 patients administered PRF-110 intra-operatively

PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery

TEL AVIV, Israel, March 16, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the year ended December 31, 2022.

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

PainReform (NASDAQ: PRFX ) stock is rocketing higher on Wednesday following an update on its delisting ordeal. A press release confirms that the company has received a letter from The Nasdaq Stock Market.

Why Is PainReform (PRFX) Stock Up 48% Today?

TEL AVIV, Israel, Feb. 07, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd.  (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announced today that on February 7, 2023, it received a letter from The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it is eligible for an additional 180 calendar day period, or until August 7, 2023, to regain compliance with the Nasdaq's minimum $1 bid price per share requirement.

PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Implements Technology Improvements Related to PRF-110 Manufacturing Process Ahead of Planned Phase 3 Clinical Trial in Bunionectomy Implements Technology Improvements Related to PRF-110 Manufacturing Process Ahead of Planned Phase 3 Clinical Trial in Bunionectomy

PainReform Provides Business Update for the Third Quarter of 2022

TEL AVIV, Israel, Sept. 01, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12th - 14th, 2022. The event will include virtual participation as well as in-person participation at the Lotte New York Palace Hotel in New York City.

PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference

On track to commence Phase 3 clinical trial in bunionectomy in the fourth quarter of 2022

PainReform Provides Business Update for the Second Quarter of 2022

TEL AVIV, Israel, April 12, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform will present at the Noble Capital Markets' Eighteenth Annual Investor Conference being held on April 20-21, 2022 at the Hard Rock Hotel & Casino in Hollywood, Florida.

PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th

TEL AVIV, Israel, March 21, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it will present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

TEL AVIV, Israel, March 17, 2022 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the year ended December 31, 2021.

PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022

TEL AVIV, Israel, Dec. 14, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will be participating in the Benzinga All Access event taking place on December 16, 2021.

PainReform CEO to Participate in the Benzinga All Access Event on December 16th

PainReform (PRFX) stock is on the move Monday with heavy trading despite a lack of news coming from the medical device company. The post PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today appeared first on InvestorPlace.

PRFX Stock: 8 Things to Know About PainReform as Shares Trend on Unusually Heavy Volume Today

Reports continued progress towards commencing Phase 3 clinical trials

PainReform Provides Business Update for the Third Quarter of 2021

TEL AVIV, Israel, Oct. 14, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) ("PainReform" or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will present at the Dawson James Securities Small Cap Growth Conference being held on October 21, 2021 at the Wyndham Grand Hotel in Jupiter, Florida.

PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021

Shifting manufacturing and scale up operation to U.S.-based Contract Development and Manufacturing Organization for PRF-110 Shifting manufacturing and scale up operation to U.S.-based Contract Development and Manufacturing Organization for PRF-110

PainReform Provides Business Update for the Second Quarter of 2021

DarkPulse, Inc.

Second Sight Medical Products

India Globalization Capital

Best high-volume penny stocks for your watchlist right now? Check these 4 out The post Highest Volume Penny Stocks to Watch Today?

Highest Volume Penny Stocks to Watch Today? Check These 4 Out

The stock price of PainReform Ltd (NASDAQ: PRFX) increased by over 60% pre-market. These are some details you should know.

PRFX Stock Increases Over 60% Pre-Market: Details You Should Know

We're seeing lots of activity from penny stock PainReform (PRFX) on Wednesday despite a lack of news from the pharmaceutical company. The post PRFX Stock: 7 Things to Know About Pharmaceutical Company PainReform Amid Heavy Trading appeared first on InvestorPlace.

PRFX Stock: 7 Things to Know About Pharmaceutical Company PainReform Amid Heavy Trading

Reports continued progress towards start of Phase 3 trials Reports continued progress towards start of Phase 3 trials

News for PainReform Ltd. Stock (PRFX)